Published in Hepatitis Weekly, August 5th, 1996
3TC (also known as Epivir or lamivudine) is an important component of the new AIDS "cocktail" therapies, in which two or more drugs which exert different kinds of selective pressures on the virus are administered together. 3TC was approved by the U.S. Food and Drug Administration (FDA) for marketing and sale on November 17, 1995, in combination with AZT for the treatment of HIV and AIDS as a "first line" therapy.
3TC also is now in clinical trials for the treatment of hepatitis B virus (HBV) in the United States, Japan,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly